16.75 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||15.60 x 100|
|Ask||18.00 x 200|
|Day's Range||16.73 - 18.08|
|52 Week Range||11.85 - 19.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $237 million.
The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA )'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. ...
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 18 cents. The biotechnology company posted revenue of $64.6 million in the period. For the year, the company reported ...
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Moody's Investors Service says a second generic version of blockbuster multiple sclerosis drug, Copaxone, was approved today, a credit negative for Teva Pharmaceutical Industries Ltd ("Teva," ...
Teva Pharmaceutical Industries Ltd. shares dropped 3% in premarket trade Tuesday after Novartis AG's Sandoz announced that the 40 mg dose of Glatopa, its generic for Teva's popular multiple sclerosis medication ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Index (PMI) data, output in the Healthcare sector is rising.
Momenta's (MNTA) stock gains as investors were relieved after the FDA classified the outcome of fourth-quarter 2017 reinspection of Pfizer's McPherson facility as Voluntary Action Indicated.
Momenta reported positive top-line results from a phase I study on M281 wherein the candidate did not show any adverse event, was well tolerated, and decreased circulating IgG levels up to 89%.
Stocks continued their strong start to 2018. Holiday sales at Barnes & Noble disappointed investors, though, and Momenta Pharmaceuticals reported a successful drug trial.
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.